CHICAGO, Nov. 14, 2017 /PRNewswire/ -- Monopar Therapeutics, Inc., an emerging biopharmaceutical company focused on developing innovative drug candidates to improve clinical outcomes in cancer ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted orphan drug designation ...

A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma. For patients with metastatic nonresectable soft tissue sarcoma (STS), the investigational compound ...

A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.

Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and ...

BATON ROUGE, LA--(Marketwired - March 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of ...

GPX-150 has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the potential for irreversible damage to the heart. Doxorubicin is currently approved by the ...